


**What is claimed is:**

1. A compound having a structure of one of the following formulae:



wherein

a dashed line represents either a single or a double bond,

L is:

- i) H,
- ii)  $-C_{1-6}$  alkyl,  $-C_{1-6}$  alkyl-OCONR<sub>2</sub>,  $-C_{1-6}$  alkyl-CONR<sub>2</sub>,  $-C_{1-6}$  alkyl-CO<sub>2</sub>R,  $-C_{1-6}$  alkyl-COR,  $-C_{1-6}$  alkyl-NRC(O)NR<sub>2</sub>,  $-C_{1-6}$  alkyl-NRC(O)OR,  $-C_{1-6}$  alkyl-NRC(O)R, and  $-C_{1-6}$  alkyl-NR<sub>2</sub>, wherein the  $C_{2-6}$  alkyl can optionally include a double bond;
- iii)  $C_{5-6}$  cycloalkyl-OCONR<sub>2</sub>,  $C_{5-6}$  cycloalkyl-CONR<sub>2</sub>,  $C_{5-6}$  cycloalkyl-CO<sub>2</sub>R,  $C_{5-6}$  cycloalkyl-COR,  $C_{5-6}$  cycloalkyl-NRC(O)NR<sub>2</sub>,  $C_{5-6}$  cycloalkyl-NRC(O)OR,  $C_{5-6}$  cycloalkyl-NRC(O)R, and  $C_{5-6}$  cycloalkyl-NR<sub>2</sub>, where the cycloalkyl ring can be substituted with from one to three  $C_{1-6}$  alkyl groups, and where the  $C_{5-6}$  cycloalkyl ring can optionally include a double bond, an oxygen, or an NR group;
- iv)  $-C_{1-6}$  alkyl- $C_{5-6}$  cycloalkyl,  $-C_{1-6}$  alkyl- $C_{5-6}$  cycloalkyl-OCONR<sub>2</sub>,  $-C_{1-6}$  alkyl- $C_{5-6}$  cycloalkyl-CONR<sub>2</sub>,  $-C_{1-6}$  alkyl- $C_{5-6}$  cycloalkyl-CO<sub>2</sub>R,  $-C_{1-6}$  alkyl- $C_{5-6}$  cycloalkyl-COR,  $-C_{1-6}$  alkyl- $C_{5-6}$  cycloalkyl-NRC(O)NR<sub>2</sub>,  $-C_{1-6}$  alkyl- $C_{5-6}$  cycloalkyl-NRC(O)OR,  $-C_{1-6}$  alkyl- $C_{5-6}$  cycloalkyl-NRC(O)R, and  $-C_{1-6}$  alkyl- $C_{5-6}$  cycloalkyl-NR<sub>2</sub>, where the cycloalkyl ring can be substituted with from one to three  $C_{1-6}$  alkyl groups, and where the  $C_{5-6}$  cycloalkyl ring can optionally include a double bond, an oxygen, or a nitrogen;
- v) 2.2.2 bicyclooctyl-OCONR<sub>2</sub>, 2.2.2 bicyclooctyl-CONR<sub>2</sub>, 2.2.2 bicyclooctyl-CO<sub>2</sub>R, 2.2.2 bicyclooctyl-COR, 2.2.2 bicyclooctyl-NRC(O)NR<sub>2</sub>, 2.2.2 bicyclooctyl-NRC(O)OR, 2.2.2 bicyclooctyl-NRC(O)R, and 2.2.2 bicyclooctyl-NR<sub>2</sub>, wherein the 2.2.2 bicyclooctyl ring can optionally include a double bond;

R is H, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyl-CO<sub>2</sub>R<sup>1</sup>, -CO<sub>2</sub>R<sup>1</sup>, CON(R<sup>1</sup>)<sub>2</sub>, or C<sub>1-6</sub> alkyl-CON(R<sup>1</sup>)<sub>2</sub>, and R<sup>1</sup> is H or C<sub>1-6</sub> alkyl;


each R<sup>2</sup> is independently H, halo, -CN, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> haloalkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, CO<sub>2</sub>R, CONR<sub>2</sub>, phenyl, pyridinyl, thiophenyl, furanyl, or imidazolyl, wherein the phenyl, pyridinyl, thiophenyl, furanyl, or imidazolyl is optionally substituted with one or more (e.g., 1 or 2) substituents selected from the group consisting of hydroxy, C<sub>1-6</sub> alkoxy, C<sub>2-8</sub> alkoxyalkyl, alkoxycarbonyl, C<sub>1-8</sub> alkyl, arylalkoxycarbonyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, carboxy, halogen, haloalkyl (e.g., CF<sub>3</sub>), N<sub>3</sub>, CN, N(R')<sub>2</sub>, SR', OCOR', N(COR')R', N(COR')COR', SCOR', S(O)<sub>2</sub>NR'<sub>2</sub>, S(O)<sub>2</sub>R', and each R' is independently H or C<sub>1-6</sub> alkyl;

R<sup>3</sup> is H, or -SO<sub>2</sub>-phenyl, wherein the phenyl is optionally substituted with one or more (e.g., one or two) substituents selected from the group consisting of hydroxy, C<sub>1-6</sub> alkoxy, C<sub>2-8</sub> alkoxyalkyl, alkoxycarbonyl, C<sub>1-8</sub> alkyl, arylalkoxycarbonyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, carboxy, halogen, haloalkyl (e.g., CF<sub>3</sub>), N<sub>3</sub>, CN, N(R')<sub>2</sub>, SR', OCOR', N(COR')R', N(COR')COR', SCOR', S(O)<sub>2</sub>NR'<sub>2</sub>, S(O)<sub>2</sub>R', and each R' is independently H or C<sub>1-6</sub> alkyl;

wherein a C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, or C<sub>2-6</sub> alkynyl moiety, wherever it occurs, can optionally be substituted with from one to three substituents which are not further substituted and which are independently selected from the group consisting of -CN, thio, aryl-C<sub>1-6</sub> alkyl, pyridinyl, ethoxymethyl-pyridinyl, indolyl, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkyl-C<sub>3-6</sub>cycloalkyl, C<sub>3-6</sub>cycloalkyl, -C<sub>1-6</sub> thioalkyl, C<sub>1-6</sub> haloalkyl, -C<sub>1-6</sub> hydroxyalkyl, -C<sub>1-6</sub> alkoxy, -C<sub>1-6</sub> alkoxy-C<sub>1-6</sub> alkoxy, -C<sub>1-6</sub> alkoxy-C<sub>1-6</sub> alkoxy-C<sub>1-6</sub> alkoxy, CO<sub>2</sub>H, CO<sub>2</sub>C<sub>1-6</sub>alkyl, CO<sub>2</sub>NH<sub>2</sub>, CO<sub>2</sub>NHC<sub>1-6</sub>alkyl, and -CO<sub>2</sub>N(C<sub>1-6</sub>alkyl)<sub>2</sub>; and


wherein if two alkyl groups reside on an amide moiety, they can optionally together form a 5-7 membered ring with the nitrogen of the amide moiety;  
or a pharmaceutically acceptable salt thereof.

2. The compound or salt of Claim 1, having a structure of Formula I:




Formula I.


3. The compound or salt of Claim 2, having a structure of Formula IA:




4. The compound or salt of Claim 1, having a structure of Formula II:




5. The compound or salt of Claim 4, having a structure of Formula IIA:



6. The compound or salt of Claim 1, having a structure of Formula III:





7. The compound or salt of Claim 6, having a structure of Formula IIIA:




8. The compound or salt of any one of Claims 1-7, wherein L is C<sub>1-6</sub>alkylCONR<sub>2</sub>.
9. The compound or salt of Claim 8, wherein L is CH<sub>2</sub>CONHMe, CH<sub>2</sub>CONMe<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>CONHMe, CH<sub>2</sub>CH<sub>2</sub>CONMe<sub>2</sub>, CH<sub>2</sub>CH(Me)CONHMe, CH<sub>2</sub>CH(Me)CONMe<sub>2</sub>, C(Me)(Et)CONHCH<sub>2</sub>CF<sub>3</sub>, CH<sub>2</sub>CONHCH<sub>2</sub>CO<sub>2</sub>H, CH<sub>2</sub>CH<sub>2</sub>CONHCH<sub>2</sub>CO<sub>2</sub>H, CH<sub>2</sub>CONHCH(Me)CO<sub>2</sub>H, CH<sub>2</sub>CH<sub>2</sub>CONHCH(Me)CO<sub>2</sub>H, CH<sub>2</sub>CONHCH(CH<sub>2</sub>OH)CO<sub>2</sub>H, CH<sub>2</sub>CH<sub>2</sub>CONHCH(CH<sub>2</sub>OH)CO<sub>2</sub>H, CH<sub>2</sub>CONHCH(CH<sub>2</sub>Ph)CO<sub>2</sub>H, CH<sub>2</sub>CH<sub>2</sub>CONHCH(CH<sub>2</sub>Ph)CO<sub>2</sub>H,


CH<sub>2</sub>CONHCH(CO<sub>2</sub>H)CH<sub>2</sub>CO<sub>2</sub>H, CH<sub>2</sub>CH<sub>2</sub>CONHCH(CO<sub>2</sub>H)CH<sub>2</sub>CO<sub>2</sub>H,  
 CH<sub>2</sub>CONHCH(CO<sub>2</sub>H)CH<sub>2</sub>CONH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>CONHCH(CO<sub>2</sub>H)CH<sub>2</sub>CONH<sub>2</sub>,  
 CH<sub>2</sub>CONHCH(CO<sub>2</sub>Me)CH<sub>2</sub>CO<sub>2</sub>H, CH<sub>2</sub>CH<sub>2</sub>CONHCH(CO<sub>2</sub>Me)CH<sub>2</sub>CO<sub>2</sub>H,  
 CH<sub>2</sub>CONHCH(CO<sub>2</sub>Me)CH<sub>2</sub>CONH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>CONHCH(CO<sub>2</sub>Me)CH<sub>2</sub>CONH<sub>2</sub>,  
 CH<sub>2</sub>CONHCH<sub>2</sub>CO<sub>2</sub>Me, CH<sub>2</sub>CH<sub>2</sub>CONHCH<sub>2</sub>CO<sub>2</sub>Me, CH<sub>2</sub>CONHCH(Me)CO<sub>2</sub>Me,  
 CH<sub>2</sub>CH<sub>2</sub>CONHCH(Me)CO<sub>2</sub>Me, CH<sub>2</sub>CONHCH(CH<sub>2</sub>OH)CO<sub>2</sub>Me,  
 CH<sub>2</sub>CH<sub>2</sub>CONHCH(CH<sub>2</sub>OH)CO<sub>2</sub>Me, CH<sub>2</sub>CONHCH(CH<sub>2</sub>Ph)CO<sub>2</sub>Me,

CH<sub>2</sub>CONHCH(CO<sub>2</sub>Me)CH<sub>2</sub>CO<sub>2</sub>Me, CH<sub>2</sub>CONHCH(CO<sub>2</sub>H)CH<sub>2</sub>CO<sub>2</sub>Me,



10. The compound or salt of any one of Claims 1-7, wherein L is C<sub>1-6</sub>alkyl-CO<sub>2</sub>R.
11. The compound or salt of Claim 10, wherein L is CH<sub>2</sub>CO<sub>2</sub>H, CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H, CH=CHCO<sub>2</sub>H, CH<sub>2</sub>CH=CHCO<sub>2</sub>H, CH(CMe<sub>3</sub>)CO<sub>2</sub>H, CH<sub>2</sub>CH(CMe<sub>3</sub>)CO<sub>2</sub>H, CH<sub>2</sub>CH(Me)CO<sub>2</sub>H, CH(Me)CO<sub>2</sub>H, CH(Me)CH<sub>2</sub>CO<sub>2</sub>H, CH<sub>2</sub>CO<sub>2</sub>Me, CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>Me, CH=CHCO<sub>2</sub>Me, CH<sub>2</sub>CH=CHCO<sub>2</sub>Me, CH(CMe<sub>3</sub>)CO<sub>2</sub>Me, CH<sub>2</sub>CH(CMe<sub>3</sub>)CO<sub>2</sub>Me, CH<sub>2</sub>CH(Me)CO<sub>2</sub>Me, CH(Me)CO<sub>2</sub>Me, CH(Me)CH<sub>2</sub>CO<sub>2</sub>Me, CH<sub>2</sub>CO<sub>2</sub>Et, CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>Et, CH=CHCO<sub>2</sub>Et, CH<sub>2</sub>CH=CHCO<sub>2</sub>Et, CH(CMe<sub>3</sub>)CO<sub>2</sub>Et, CH<sub>2</sub>CH(CMe<sub>3</sub>)CO<sub>2</sub>Et, CH<sub>2</sub>CH(Me)CO<sub>2</sub>Et, CH(Me)CO<sub>2</sub>Et, CH(Me)CH<sub>2</sub>CO<sub>2</sub>Et, CH<sub>2</sub>CO<sub>2</sub>CMe<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>CMe<sub>3</sub>, CH=CHCO<sub>2</sub>CMe<sub>3</sub>, CH<sub>2</sub>CH=CHCO<sub>2</sub>CMe<sub>3</sub>, CH(CMe<sub>3</sub>)CO<sub>2</sub>CMe<sub>3</sub>, CH<sub>2</sub>CH(CMe<sub>3</sub>)CO<sub>2</sub>CMe<sub>3</sub>, CH<sub>2</sub>CH(Me)CO<sub>2</sub>CMe<sub>3</sub>, CH(Me)CO<sub>2</sub>CMe<sub>3</sub>, or CH(Me)CH<sub>2</sub>CO<sub>2</sub>CMe<sub>3</sub>.
12. The compound or salt of any one of Claims 1-7, wherein L is C<sub>1-6</sub>alkyl-NRC(O)R, C<sub>1-6</sub>alkyl-NRC(O)OR, or C<sub>1-6</sub>alkyl-NRC(O)NR.
13. The compound or salt of claim 12, wherein L is CH<sub>2</sub>CH<sub>2</sub>NHCOMe, CH<sub>2</sub>CH<sub>2</sub>NHCO<sub>2</sub>CMe<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>NHCONHMe, CH<sub>2</sub>CH<sub>2</sub>NHCO<sub>2</sub>Me, or CH<sub>2</sub>CH<sub>2</sub>NHCONMe<sub>2</sub>.
14. The compound or salt of any one of Claims 1-7, wherein L is X-A; X is a bond, CH<sub>2</sub>, or







15. The compound or salt of Claim 14, wherein R is H, Me, Et, or CMe<sub>3</sub>.

16. The compound or salt of any one of Claims 1-7, wherein L is C<sub>5-6</sub>cycloalkyl-CONR<sub>2</sub>, C<sub>5-6</sub>cycloalkyl-NRCONR<sub>2</sub>, C<sub>5-6</sub>cycloalkyl-NRCOR, C<sub>5-6</sub>cycloalkyl-COR, or C<sub>5-6</sub>cycloalkyl-NR<sub>2</sub>.



17. The compound or salt of any one of Claims 1-7 and 16, wherein L is X-A; X is a bond, CH<sub>2</sub>, or






each  $R^a$  is independently H or Me; and

each  $R^b$  is independently H, Me,  $CMe_3$ ,  $(CH_2CH_2O)_3Et$ ,  $CH_2O(CH_2CH_2O)_2Et$ ,  $CH_2CH_2OCH_2CH_2O(CH_2)_3Me$ ,  $(CH_2)_5O(CH_2)_4Me$ ,  $(CH_2)_4O(CH_2)_4Me$ ,  $CH_2CH_2O(CH_2)_5OEt$ ,  $CH_2CH_2OCH_2CH_2O(CH_2)_4Me$ ,  $(CH_2)_5OCH_2CH_2OEt$ ,  $(CH_2)_4OCH_2CH_2OEt$ ,

$CH_2OCH_2CH_2O(CH_2)_4Me$ , pyridinyl, or , or .


18. The compound or salt of any one of Claims 1-7, wherein



E is  $CO_2R^a$ ,  $CONR^aR^b$ ,  $NR^aR^b$ ,  $NR^aCONR^aR^b$ ,  $NR^aCOR^a$ ; or  $NR^aCO_2R^a$ ;

each  $R^a$  is independently H, Me, Et, or  $CMe_3$ ; and

each  $R^b$  is independently H, Me, Et,  $CH_2CONHMe$ ,  $CH_2CONMe_2$ , or  $CH_2CONH_2$ .



19. The compound or salt of Claim 18, wherein L is

20. The compound or salt of any one of Claims 1-19, wherein at least one  $R^2$  is F.

21. The compound or salt of any one of Claims 1-20, wherein at least one  $R^2$  is Cl.

22. The compound or salt of Claim 20, wherein one  $R^2$  is F and the other  $R^2$  is Cl or F.

23. The compound or salt of any one of Claims 1-21, wherein at least one  $R^2$  is H.

24. The compound or salt of Claim 23, wherein each  $R^2$  is H.

25. The compound or salt of any one of Claims 1-21 and 23, wherein at least one  $R^2$  is phenyl, pyridinyl, hydroxyphenyl,  $CF_3$ ,  $-C\equiv C-CH_2cyclopropyl$ ,  $-C\equiv C-cyclopropyl$ , furanyl, thienyl,

methyl, imidazolyl,  $\text{CH}(\text{CH}_3)_2$ ,  $-(\text{CH}_2)_2\text{pyridinyl}$ ,  $-\text{C}\equiv\text{C}-(\text{CH}_2)_2\text{SCH}_3$ ,  $\text{CN}$ ,  $-(\text{CH}_2)_4\text{SCH}_3$ ,  $-(\text{CH}_2)_4\text{CN}$ ,  $\text{CO}_2\text{H}$ ,  $\text{CONHCH}_3$ ,  $-\text{C}\equiv\text{C}-(\text{CH}_2)_2\text{CN}$ ,  $\text{CON}(\text{CH}_3)_2$ ,  $\text{CO}_2\text{CH}_2\text{CH}_3$ ,  $-\text{CH}=\text{CH}_2$ , fluoropyridinyl, chloropyridinyl, or cyanopyridinyl.

26. The compound or salt of any one of Claims 1-25, wherein  $\text{R}^3$  is H.
27. A compound or pharmaceutically acceptable salt thereof having a structure selected from the group consisting of A1, A2, A3, A4, A5, A6, A7, A8, A9, A10, A11, A12, A13, A14, A15, A16, A17, A18, A19, and A20.
28. A compound or pharmaceutically acceptable salt thereof, having a structure selected from the group consisting of B1, B2, B3, B4, B5, B6, B7, B8, B9, B10, B11, B12, B13, B14, B15, B16, B17, B18, B19, B20, B21, B22, B23, B24, B25, B26, B27, B28, B29, B30, B31, B32, B33, B34, B35, B36, B37, B38, B39, B40, B41, B42, B43, B44, B45, B46, B47, B48, B49, B50, B51, B52, B54, B55, B56, B57, B58, B59, B60, B61, B62, B63, B64, B65, B66, B67, B68, B69, B70, B71, B72, B73, B74, B75, B76, B77, B78, B79, B80, B81, B82, B83, B84, B85, B86, B87, B88, B89, B90, B91, B92, B93, B94, B95, B96, B97, B98, B99, B100, B101, B102, and B103.
29. The compound or salt of claim 28 selected from the group consisting of B25, B26, B27, B28, B29, B30, B50, B31, B32, B33, B34, B35, B36, B100, B52, B37, B38, B39, B40, B41, B42, B43, B44, B45, B46, B47, and B49.
30. The compound or salt of claim 28 selected from the group consisting of B1, B2, B3, B4, B5, B6, B7, B8, B9, B10, B11, B12, B13, B14, B15, B16, B17, B18, B19, B20, B21, B22, B23, B24, B48, B51, B54, B55, B56, B57, B58, B59, B60, B61, B62, B63, B64, B65, B66, B67, B68, B69, B70, B71, B72, B73, B74, B75, B76, B77, B78, B79, B80, B81, B82, B83, B84, B85, B86, B87, B88, B89, B90, B91, B92, B93, B94, B95, B96, B97, B98, B99, B101, B102, and B103.
31. A compound or pharmaceutically acceptable salt thereof, having a structure selected from the group consisting of B120, B121, B122, B123, B124, B125, B126, B127, B128, B129, B130, B131, B132, B133, B134, B135, B136, B137, B138, B139, B140, B141, B142, B143, B144, B145, B146, B147, B148, B149, B150, B151, B152, B153, B154, B160, B161, B162, B163, B164, B165, B166, B167, B168, B169, B170, B171, B172, B173, B174, B175, B176, B177, B178, B179, B180, B181, B182, B183, B184, B185, B186, B187, B188, B190, B191, B192, B193, B194, B195, B196, B197, B198, B199, B200, B201, B202, B203, B204, B205, B206, B207, B208, B209, B210, B211, B212, B213, B214, B215, B216, B217, B218, B219, B220, B221, and B222.
32. The compound or salt of claim 31 selected from the group consisting of B120, B121, B122, B123, B124, B126, B127, B128, B129, B213, B130, B131, B132, B133, B134, B135, B136,

- B137, B138, B139, B221, B140, B141, B143, B144, B146, B148, B149, B222, B166, B167, B168, B171, B172, B188, B194, B195, B198, B199, B200, B205, B206, B207, and B208.
33. The compound or salt of claim 31 selected from the group consisting of B120, B122, B123, B124, B127, B130, B131, B132, B133, B135, B136, B137, B138, B139, B140, B143, B144, B213, B221, and B222.
34. A compound, or pharmaceutically acceptable salt thereof, having structure selected from the group consisting of C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, C15, C16, C17, and C18.
35. A compound as recited in Table A, or a pharmaceutically acceptable salt thereof.
36. A compound as recited in Table B, or a pharmaceutically acceptable salt thereof.
37. A compound as recited in Table C, or a pharmaceutically acceptable salt thereof.
38. A compound as recited in Table D, or a pharmaceutically acceptable salt thereof.
39. A method of treating or preventing influenza in a subject, comprising administering to said subject a safe and effective amount of a compound or salt of any one of Claims 1-38.
40. A method of reducing the amount of influenza viruses in a biological sample or in a subject, comprising administering to said biological sample or subject a safe and effective amount of a compound or salt of any one of Claims 1-38.
41. The method of Claim 39 or 40, wherein an influenza vaccine is administered to the subject before, after, or concurrent with the administration of the compound.
42. The method of any one of Claims 39 to 41, wherein the compound is administered via a liposome or niosome.
43. The method of Claim 42, wherein the liposome is a small unilamellar vesicle.
44. The method of Claim 42, wherein the liposome is administered via intravenous injection or via inhalation.
45. The method of any one of Claims 39-41, wherein the compound is administered via inhalation.
46. The method of Claim 45, wherein the compound is provided in the form of porous particles sized to deliver the particles to the alveolar region of the lungs.
47. Use of a compound or salt of any one of Claims 1-38 in the preparation of a medicament for treating or preventing influenza.
48. Use of a compound or salt of any of Claims 1-38 in the preparation of a medicament for reducing the amount of influenza viruses in a patient.
49. The use of Claim 47 or 48, further comprising use of one or more additional active agents selected from the group consisting of neuraminidase (NA) inhibitors, ion channel (M2) inhibitors, and polymerase (PB1) inhibitors.

50. The use of claim 49, wherein the compound or salt and the one or more additional active agents are co-formulated.
51. The use of any one of Claims 47-50, wherein the medicament is in the form of a liposomal formulation.
52. The use of Claim 51, wherein the liposomal formulation comprises small unilamellar vesicles.
53. The use of any one of Claims 47-52, wherein the medicament is formulated for intravenous administration.
54. The use of any one of Claims 47-52, wherein the medicament is formulated for pulmonary or intranasal administration.
55. The use of Claim 54, wherein the medicament comprises porous particles sized for pulmonary administration to the alveolar region of the lungs.
56. A pharmaceutical composition for treatment of an influenza infection in a subject, comprising a compound or salt of any of Claims 1-38 and a pharmaceutically acceptable carrier, wherein the composition optionally comprises an additional agent selected from neuraminidase inhibitors, ion channel inhibitors, and polymerase inhibitors.
57. A method of inhibiting an influenza virus in a cell comprising contacting the virus in the cell with a compound or salt of any one of claims 1-38 in an amount effective to inhibit the virus.
58. The method of claim 57, wherein the compound or salt inhibits at least one of free virus, pre-mRNA bound PB2, or trimeric polymerase complex.
59. The method of claim 58, wherein the compound or salt inhibits each of free virus, pre-mRNA bound PB2, and trimeric polymerase complex.